vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and COASTAL FINANCIAL CORP (CCB). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $138.0M, roughly 1.4× COASTAL FINANCIAL CORP). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -5.8%). COASTAL FINANCIAL CORP produced more free cash flow last quarter ($246.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -3.6%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.

AXSM vs CCB — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.4× larger
AXSM
$196.0M
$138.0M
CCB
Growing faster (revenue YoY)
AXSM
AXSM
+70.8% gap
AXSM
65.0%
-5.8%
CCB
More free cash flow
CCB
CCB
$264.9M more FCF
CCB
$246.1M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
-3.6%
CCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
CCB
CCB
Revenue
$196.0M
$138.0M
Net Profit
$-28.6M
Gross Margin
Operating Margin
-13.8%
12.4%
Net Margin
-14.6%
Revenue YoY
65.0%
-5.8%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55
$0.84

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
CCB
CCB
Q4 25
$196.0M
$138.0M
Q3 25
$171.0M
$144.7M
Q2 25
$150.0M
$119.4M
Q1 25
$121.5M
$139.5M
Q4 24
$118.8M
$146.5M
Q3 24
$104.8M
$151.1M
Q2 24
$87.2M
$135.3M
Q1 24
$75.0M
$148.4M
Net Profit
AXSM
AXSM
CCB
CCB
Q4 25
$-28.6M
Q3 25
$-47.2M
$13.6M
Q2 25
$-48.0M
$11.0M
Q1 25
$-59.4M
$9.7M
Q4 24
$-74.9M
Q3 24
$-64.6M
$13.5M
Q2 24
$-79.3M
$11.6M
Q1 24
$-68.4M
$6.8M
Operating Margin
AXSM
AXSM
CCB
CCB
Q4 25
-13.8%
12.4%
Q3 25
-27.0%
12.4%
Q2 25
-24.5%
12.0%
Q1 25
-46.9%
8.4%
Q4 24
-61.1%
11.7%
Q3 24
-59.8%
10.8%
Q2 24
-89.5%
11.1%
Q1 24
-89.7%
5.9%
Net Margin
AXSM
AXSM
CCB
CCB
Q4 25
-14.6%
Q3 25
-27.6%
9.4%
Q2 25
-32.0%
9.2%
Q1 25
-48.9%
7.0%
Q4 24
-63.1%
Q3 24
-61.7%
8.9%
Q2 24
-91.0%
8.6%
Q1 24
-91.1%
4.6%
EPS (diluted)
AXSM
AXSM
CCB
CCB
Q4 25
$-0.55
$0.84
Q3 25
$-0.94
$0.88
Q2 25
$-0.97
$0.71
Q1 25
$-1.22
$0.63
Q4 24
$-1.54
$0.95
Q3 24
$-1.34
$0.97
Q2 24
$-1.67
$0.84
Q1 24
$-1.44
$0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
CCB
CCB
Cash + ST InvestmentsLiquidity on hand
$322.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$491.0M
Total Assets
$689.8M
$4.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
CCB
CCB
Q4 25
$322.9M
Q3 25
$325.3M
Q2 25
$303.0M
Q1 25
$300.9M
Q4 24
$315.4M
Q3 24
$327.3M
Q2 24
$315.7M
Q1 24
$331.4M
Stockholders' Equity
AXSM
AXSM
CCB
CCB
Q4 25
$88.3M
$491.0M
Q3 25
$73.7M
$475.3M
Q2 25
$73.1M
$461.7M
Q1 25
$53.2M
$449.9M
Q4 24
$57.0M
$438.7M
Q3 24
$92.9M
$331.9M
Q2 24
$102.9M
$316.7M
Q1 24
$144.0M
$303.7M
Total Assets
AXSM
AXSM
CCB
CCB
Q4 25
$689.8M
$4.7B
Q3 25
$669.3M
$4.6B
Q2 25
$639.8M
$4.5B
Q1 25
$596.7M
$4.3B
Q4 24
$568.5M
$4.1B
Q3 24
$561.5M
$4.1B
Q2 24
$548.2M
$4.0B
Q1 24
$545.7M
$3.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
CCB
CCB
Operating Cash FlowLast quarter
$-18.7M
$254.6M
Free Cash FlowOCF − Capex
$-18.7M
$246.1M
FCF MarginFCF / Revenue
-9.6%
178.3%
Capex IntensityCapex / Revenue
0.0%
6.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$436.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
CCB
CCB
Q4 25
$-18.7M
$254.6M
Q3 25
$1.0M
$59.0M
Q2 25
$-32.4M
$66.0M
Q1 25
$-43.4M
$71.7M
Q4 24
$-26.2M
$259.8M
Q3 24
$-18.6M
$62.6M
Q2 24
$-30.1M
$72.1M
Q1 24
$-53.5M
$56.8M
Free Cash Flow
AXSM
AXSM
CCB
CCB
Q4 25
$-18.7M
$246.1M
Q3 25
$988.0K
$57.4M
Q2 25
$-32.4M
$64.0M
Q1 25
$-43.7M
$68.9M
Q4 24
$-26.2M
$249.9M
Q3 24
$-18.7M
$60.2M
Q2 24
$-30.2M
$69.5M
Q1 24
$-53.6M
$55.0M
FCF Margin
AXSM
AXSM
CCB
CCB
Q4 25
-9.6%
178.3%
Q3 25
0.6%
39.7%
Q2 25
-21.6%
53.6%
Q1 25
-36.0%
49.4%
Q4 24
-22.1%
170.6%
Q3 24
-17.9%
39.8%
Q2 24
-34.6%
51.3%
Q1 24
-71.4%
37.1%
Capex Intensity
AXSM
AXSM
CCB
CCB
Q4 25
0.0%
6.1%
Q3 25
0.0%
1.2%
Q2 25
0.0%
1.7%
Q1 25
0.3%
2.0%
Q4 24
0.0%
6.8%
Q3 24
0.1%
1.6%
Q2 24
0.1%
1.9%
Q1 24
0.1%
1.2%
Cash Conversion
AXSM
AXSM
CCB
CCB
Q4 25
Q3 25
4.34×
Q2 25
5.99×
Q1 25
7.37×
Q4 24
Q3 24
4.65×
Q2 24
6.22×
Q1 24
8.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

CCB
CCB

Other$74.7M54%
Baa S Credit Enhancements$47.3M34%
Baa S Program Income$8.4M6%
Transaction Fees$4.9M4%
Servicing And Other Baa S Fees$1.6M1%
Baa S Fraud Enhancements$1.1M1%

Related Comparisons